Atlas Trials

Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib

Clinical trial NCT04757259 · NO_LONGER_AVAILABLE

Trial details

NCT number
NCT04757259
Sponsor
Alexion Pharmaceuticals, Inc.
Status
NO_LONGER_AVAILABLE
Study type
EXPANDED_ACCESS
Relapsed/Refractory Chronic Lymphocytic LeukemiaNon-hodgkin's Lymphoma

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.